Developer/manufacturer

2021/2/9　WHO　The COVID-19 candidate vaccine landscape

Route 注射方法
IM: intramuscular 筋肉注射
SC: subcutaneous injection 皮下注射
ID: intradermal injection   皮内注射
IV: intraveneous   静脈内注射

　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　日本の接種承認一覧

Developer/manufacturer Platform Type doses Timing
　days Route Phase 承認
# EUA 　

AstraZeneca + University of Oxford Non-Replicating Viral Vector ChAdOx1-S- (AZD1222) (Covishield) 1-2 0, 28 IM Ⅲ
UK 2020/12/30
EU   2021/1/29
WHO 2021/2/15
日本 2021/5/21
　

CanSino Biological Inc./Beijing Institute of Biotechnology Non-Replicating Viral Vector Adenovirus Type 5 Vector 1 　 IM Ⅲ
中国 2021/2/26

有効性 65.28%
5/18 接種開始

Gamaleya Research Institute ; Health Ministry of the Russian Federation Non-Replicating Viral Vector Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S) 2 0, 21 IM Ⅲ　
Sputnik V
ロシア　2020/8
　

Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"　　　(Russia) Protein Subunit EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) 2 0, 21 IM Ⅰ/Ⅱ
EpiVacCorona
ロシア　2020/10
　

Janssen Pharmaceutical (Johnson & Johnson) Non-Replicating Viral Vector Ad26COVS1 1 　 IM Ⅲ
FDA 2021/2/27#
WHO 2021/3/12
2021/5/24日本申請

Sinovac Research and Development Inactivated Inactivated 2 0, 14 IM Ⅲ
中国 2021/2/6
WHO 2021/6/1

中国2件目

Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products Inactivated Inactivated 2 0, 21 IM Ⅲ
中国 2021/2/26

有効性 72.51%

Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products Inactivated Inactivated(Vero cell) 2 0, 21 IM Ⅲ　
中国 2020/12/31
WHO 2021/5/7
　

Bharat Biotech International (インド） Inactivated Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) 2 0, 14 IM Ⅲ　
Covaxin
インド 2021/1/3
WHO 2021/11/3

　

Moderna/NIAID（米国立アレルギー感染症研究所） RNA mRNA -1273 2 0, 28 IM Ⅲ
FDA 2020/12/17
                  EUA
EU 2021/1/6
日本 2021/5/21

FDA 12～17　承認延期
2021/11/19 18歳以上の追加接種のEUA
2022/1/26
オミクロン特化ワクチンの治験開始

Pfizer/BioNTech
+ Fosun Pharma （上海復星医薬） RNA BNT162 (3 LNP-mRNAs )
製品名：COMIRNATY
2 0, 28 IM Ⅲ
UK 2020/12/2
FDA 2020/12/11
                 EUA
FDA 2021/8/23　
EU 2020/12/21
WHO 2020/12/31
日本 2021/2/14

FDA 2021/5/10
12～15歳も
FDA正式承認は16歳以上

2021/11/19 18歳以上の追加接種のEUA
2021/12/9 FDA 16-17の追加接種のEUA
2022/1/3 FDA 12～15の追加接種のEUA
2022/1/25
オミクロン特化ワクチンの治験開始

Novavax（米） Protein Subunit SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M) 2 0, 21 IM Ⅲ
WHO 2021/12/17 EUL
EU　2021/12/20
韓国 2022/1/12
日本　2022/4/19
FDA　2022/7/13
　

University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy Replicating Viral Vector DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD ) 1 　 IN Ⅱ 　　

Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences Protein Subunit Recombinant SARS-CoV-2 vaccine (CHO Cell) 2 or
3 0, 28
0, 28, 56 IM Ⅲ　　　

CureVac AG（独） RNA CVnCoV Vaccine 2 0, 28 IM Ⅲ 　　

Institute of Medical Biology + Chinese Academy of Medical Sciences Inactivated SARS-CoV-2 vaccine (vero cells 2 0, 28 IM Ⅲ　　　

Research Institute fo Bological Safety Problems, Rep. of Kazakhstan Inactivated QazCovid-in® - COVID-19 inactivated vaccine 2 0, 21 IM Ⅲ 　　

Beijing Minhai Biotechnology Inactivated Inactivated SARS-CoV-2 vaccine (Vero cell) 1,2 or 3 　 IM Ⅱ 　　

Inovio Pharmaceuticals (米）+ International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd DNA INO-4800+electroporation 2 0, 28 ID Ⅱ/Ⅲ 　　

Osaka University/ AnGes/ Takara Bio DNA AG0301-COVID19 2 0, 14 IM Ⅱ/Ⅲ 　　

Zydus Cadila(インド） DNA nCov vaccine 3 0, 28, 56 ID Ⅲ 　　

Genexine Consortium (韓国） DNA DNA Vaccine (GX-19) 2 0, 28 IM Ⅰ/Ⅱ 　　

Kentucky Bioprocessing（米） Protein Subunit KBP-COVID-19 (RBD-based) 2 0, 21 IM Ⅰ/Ⅱ 　　

Sanofi Pasteur/GSK Protein Subunit SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (baculovirus production) 2 0, 21 IM Ⅰ/Ⅱ 　　

Biological E Ltd　(インド） Protein Subunit BECOV2 2 0, 28 IM Ⅰ/Ⅱ　　　

Israel Institute for Biological Research Replicating Viral Vector rVSV-SARS-CoV-2-S Vaccine 1 　 IM Ⅰ/Ⅱ 　　

Arcturus Therapeutics （米） RNA ARCT-021 　　 IM Ⅱ 　　

Serum Institute of India + Accelagen Pty + SpyBiotech Virus like particle RBD-HBsAg VLPs 2 0, 28 IM Ⅰ/Ⅱ 　　

Symvivo Corporation カナダ DNA based bacTRL-Spike oral DNA vaccine 1 　 oral Ⅰ 　　

ImmunityBio, Inc & Nantkwest Inc　米 Non-Replicating Viral Vector hAd5-S-Fusion+N-ETSD vaccine 1-2 　 SC or Oral Ⅰ　　　

ReiThera（伊）/LEUKOCARE（独）/Univercells（ベルギー） Non-Replicating Viral Vector GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S) 1 　 IM Ⅰ 　　

Vaxart　米 Non-Replicating Viral Vector VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform 2 0, 28 oral Ⅰ 　　

University of Munich (Ludwig-Maximilians) Non-Replicating Viral Vector MVA-SARS-2-5 2 0, 28 IM Ⅰ 　　

Clover Biopharmaceuticals Inc./GSK/Dynavax SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant (Native like Trimeric subunit Spike Protein vaccine)   Native like Trimeric subunit Spike Protein vaccine 2 0, 21 IM Ⅱ/Ⅲ 　　

Vaxine Pty Ltd（豪） Protein Subunit COVAX-19® Recombinant spike protein + adjuvant 1 　 IM Ⅰ 　　

University of Queensland/CSL（豪）/Seqirus（英） Protein Subunit MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 2 0, 28 IM Ⅰ 　　

Medigen Vaccine Biologics（台湾）/NIAID/Dynavax Protein Subunit MVC-COV1901 (S-2P protein + CpG 1018) 2 0, 28 IM Ⅱ 　　

Instituto Finlay de Vacunas, Cuba Protein Subunit FINLAY-FR anti-SARS-CoV-2 Vaccine (RBD + adjuvant) 2 0, 28 IM Ⅱ 　　

West China Hospital, Sichuan University Protein Subunit RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell) 2 0, 28 IM Ⅱ 　　

University Hospital Tuebingen　独 Protein Subunit IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides) 1 　 SC Ⅰ 　　

COVAXX + United Biomedical Inc Protein Subunit UB-612 (Multitope peptide based S1-RBD-protein based vaccine) 2 0, 28 IM Ⅱ/Ⅲ 　　

Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + Univeristy of Pittsburgh Replicating Viral Vector V591-001 - Measles-vector based (TMV-o38) 1-2 0
0, 28 IM Ⅰ/Ⅱ 　　

Imperial College London RNA LNP-nCoVsaRNA 2 　 IM Ⅰ 　　

Academy of Military Science (AMS), Walvax Biotechnology （云南沃森生物）and Suzhou Abogen Biosciences RNA SARS-CoV-2 mRNA vaccine (ARCoV) 2 0, 14
or
0, 28 IM Ⅰ 　　

Medicago（カナダ　田辺三菱製薬） VLP Coronavirus-Like Particle COVID-19 (CoVLP) 2 0, 21 IM Ⅱ/Ⅲ
2022/2/24　
　　カナダ承認
　

Shenzhen Geno-Immune Medical Institute   Viral vector (Replicating) + APC Covid-19/aAPC vaccine.   The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs). 3
　
0, 14, 28 SC Ⅰ 　　

Shenzhen Geno-Immune Medical Institute Viral vector (Non-replicating) + APC LV-SMENP-DC vaccine.   Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens. １　 SC & IV Ⅰ/Ⅱ 　　

Adimmune Corporation Protein subunit AdimrSC-2f (recombinant RBD +/- Aluminium) 　　　 Ⅰ 　　

Entos Pharmaceuticals Inc. DNA based Covigenix VAX-001 - DNA vaccines + proteo-lipid vehicle (PLV) formulation ２
　
0, 14 IM Ⅰ 　　

Providence Health & Services DNA based CORVax - Spike (S) Protein Plasmid DNA Vaccine 2 0, 14 ID Ⅰ 　　

Chulalongkorn University RNA based ChulaCov19 mRNA vaccine 2 0, 21 IM Ⅰ 　　

City of Hope Medical Center + National Cancer Institute Viral vector (Non-replicating) COH04S1 (MVA-SARS-2-S) - Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2 1-2 0, 28 IM Ⅰ 　　

Aivita Biomedical, Inc.
National Institute of Health Research and Development, Ministry of Health Republic of Indonesia Viral vector (Replicating) + APC Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF 1 　 IM Ⅰ/Ⅱ 　　

Codagenix/Serum Institute of India Live attenuated virus COVI-VAC 1
2
0,28 IN Ⅰ 　　

Center for Genetic Engineering and Biotechnology (CIGB) Protein subunit CIGB-669 (RBD+AgnHB) 3 0,14,28 or
0,28,56 IM Ⅰ/Ⅱ 　　

Center for Genetic Engineering and Biotechnology (CIGB) Protein subunit CIGB-66 (RBD+aluminium hydroxide)   3 0,14,28 or
0,28,56 IM Ⅰ/Ⅱ 　　

Valneva, National Institute for Health Research, United Kingdom Inactivated Virus VLA2001 2 0,21 IM Ⅰ/Ⅱ 　　

Cellid Co., Ltd. Viral vector (Replicating) AdCLD-CoV19 (adenovirus vector) 1 　 IM Ⅰ/Ⅱ 　　

GeneOne Life Science, Inc. DNA based vaccine GLS-5310 2 0,56 or
0,84 ID Ⅰ/Ⅱ 　　

Nanogen Pharmaceutical Biotechnology Protein subunit Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted 2 0,21 IM Ⅰ/Ⅱ 　　

Shionogi Protein subunit Recombinant protein vaccine S-268019 (using Baculovirus expression vector system) 2 2,21 IM Ⅰ/Ⅱ 　　

Altimmune, Inc. Viral vector (Non-replicating) AdCOVID, Adenovirus-based platform expresses the receptor-binding domain (RBD) of the Sars-Cov-2 spike protein 1-2 　 IN Ⅰ 　　

University Medical Center Groningen + Akston Biosciences Inc. Protein subunit SARS-CoV-2-RBD-Fc fusion protein 　　 SC or IM Ⅰ/Ⅱ 　　

Erciyes University Inactivated Virus ERUCOV-VAC, inactivated virus 2 0,21 IM Ⅰ 　　

Vaccine and Infectious Disease Organization (VIDO) +Seppic and the Vaccine Formulation Institute (VFI) Protein subunit COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant 2 0,28 IM Ⅰ/Ⅱ 　　

Developer/manufacturer	Platform	Type	doses	Timing 　days	Route	Phase	承認 # EUA
AstraZeneca + University of Oxford	Non-Replicating Viral Vector	ChAdOx1-S- (AZD1222) (Covishield)	1-2	0, 28	IM	Ⅲ	UK 2020/12/30 EU 2021/1/29 WHO 2021/2/15 日本 2021/5/21
CanSino Biological Inc./Beijing Institute of Biotechnology	Non-Replicating Viral Vector	Adenovirus Type 5 Vector	1		IM	Ⅲ	中国 2021/2/26	有効性 65.28% 5/18 接種開始
Gamaleya Research Institute ; Health Ministry of the Russian Federation	Non-Replicating Viral Vector	Gam-COVID-Vac Adeno-based (rAd26-S+rAd5-S)	2	0, 21	IM	Ⅲ	Sputnik V ロシア　2020/8
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"　　　(Russia)	Protein Subunit	EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19)	2	0, 21	IM	Ⅰ/Ⅱ	EpiVacCorona ロシア　2020/10
Janssen Pharmaceutical (Johnson & Johnson)	Non-Replicating Viral Vector	Ad26COVS1	1		IM	Ⅲ	FDA 2021/2/27# WHO 2021/3/12	2021/5/24日本申請
Sinovac Research and Development	Inactivated	Inactivated	2	0, 14	IM	Ⅲ	中国 2021/2/6 WHO 2021/6/1	中国2件目
Sinopharm + China National Biotec Group Co + Wuhan Institute of Biological Products	Inactivated	Inactivated	2	0, 21	IM	Ⅲ	中国 2021/2/26	有効性 72.51%
Sinopharm + China National Biotec Group Co + Beijing Institute of Biological Products	Inactivated	Inactivated(Vero cell)	2	0, 21	IM	Ⅲ	中国 2020/12/31 WHO 2021/5/7
Bharat Biotech International (インド）	Inactivated	Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152)	2	0, 14	IM	Ⅲ	Covaxin インド 2021/1/3 WHO 2021/11/3
Moderna/NIAID（米国立アレルギー感染症研究所）	RNA	mRNA -1273	2	0, 28	IM	Ⅲ	FDA 2020/12/17 EUA EU 2021/1/6 日本 2021/5/21	FDA 12～17　承認延期 2021/11/19 18歳以上の追加接種のEUA 2022/1/26 オミクロン特化ワクチンの治験開始
Pfizer/BioNTech + Fosun Pharma （上海復星医薬）	RNA	BNT162 (3 LNP-mRNAs ) 製品名：COMIRNATY	2	0, 28	IM	Ⅲ	UK 2020/12/2 FDA 2020/12/11 EUA FDA 2021/8/23　 EU 2020/12/21 WHO 2020/12/31 日本 2021/2/14	FDA 2021/5/10 12～15歳も FDA正式承認は16歳以上 2021/11/19 18歳以上の追加接種のEUA 2021/12/9 FDA 16-17の追加接種のEUA 2022/1/3 FDA 12～15の追加接種のEUA 2022/1/25 オミクロン特化ワクチンの治験開始
Novavax（米）	Protein Subunit	SARS-CoV-2 rS/Matrix M1-Adjuvant (Full length recombinant SARS CoV-2 glycoprotein nanoparticle vaccine adjuvanted with Matrix M)	2	0, 21	IM	Ⅲ	WHO 2021/12/17 EUL EU　2021/12/20 韓国 2022/1/12 日本　2022/4/19 FDA　2022/7/13
University of Hong Kong, Xiamen University and Beijing Wantai Biological Pharmacy	Replicating Viral Vector	DelNS1-2019-nCoV-RBD-OPT1 (Intranasal flu-based-RBD )	1		IN	Ⅱ
Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbiology, Chinese Academy of Sciences	Protein Subunit	Recombinant SARS-CoV-2 vaccine (CHO Cell)	2 or 3	0, 28 0, 28, 56	IM	Ⅲ
CureVac AG（独）	RNA	CVnCoV Vaccine	2	0, 28	IM	Ⅲ
Institute of Medical Biology + Chinese Academy of Medical Sciences	Inactivated	SARS-CoV-2 vaccine (vero cells	2	0, 28	IM	Ⅲ
Research Institute fo Bological Safety Problems, Rep. of Kazakhstan	Inactivated	QazCovid-in® - COVID-19 inactivated vaccine	2	0, 21	IM	Ⅲ
Beijing Minhai Biotechnology	Inactivated	Inactivated SARS-CoV-2 vaccine (Vero cell)	1,2 or 3		IM	Ⅱ
Inovio Pharmaceuticals (米）+ International Vaccine Institute + Advaccine (Suzhou) Biopharmaceutical Co., Ltd	DNA	INO-4800+electroporation	2	0, 28	ID	Ⅱ/Ⅲ
Osaka University/ AnGes/ Takara Bio	DNA	AG0301-COVID19	2	0, 14	IM	Ⅱ/Ⅲ
Zydus Cadila(インド）	DNA	nCov vaccine	3	0, 28, 56	ID	Ⅲ
Genexine Consortium (韓国）	DNA	DNA Vaccine (GX-19)	2	0, 28	IM	Ⅰ/Ⅱ
Kentucky Bioprocessing（米）	Protein Subunit	KBP-COVID-19 (RBD-based)	2	0, 21	IM	Ⅰ/Ⅱ
Sanofi Pasteur/GSK	Protein Subunit	SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (baculovirus production)	2	0, 21	IM	Ⅰ/Ⅱ
Biological E Ltd　(インド）	Protein Subunit	BECOV2	2	0, 28	IM	Ⅰ/Ⅱ
Israel Institute for Biological Research	Replicating Viral Vector	rVSV-SARS-CoV-2-S Vaccine	1		IM	Ⅰ/Ⅱ
Arcturus Therapeutics （米）	RNA	ARCT-021			IM	Ⅱ
Serum Institute of India + Accelagen Pty + SpyBiotech	Virus like particle	RBD-HBsAg VLPs	2	0, 28	IM	Ⅰ/Ⅱ
Symvivo Corporation カナダ	DNA based	bacTRL-Spike oral DNA vaccine	1		oral	Ⅰ
ImmunityBio, Inc & Nantkwest Inc　米	Non-Replicating Viral Vector	hAd5-S-Fusion+N-ETSD vaccine	1-2		SC or Oral	Ⅰ
ReiThera（伊）/LEUKOCARE（独）/Univercells（ベルギー）	Non-Replicating Viral Vector	GRAd-COV2 (Replication defective Simian Adenovirus (GRAd) encoding S)	1		IM	Ⅰ
Vaxart　米	Non-Replicating Viral Vector	VXA-CoV2-1 Ad5 adjuvanted Oral Vaccine platform	2	0, 28	oral	Ⅰ
University of Munich (Ludwig-Maximilians)	Non-Replicating Viral Vector	MVA-SARS-2-5	2	0, 28	IM	Ⅰ
Clover Biopharmaceuticals Inc./GSK/Dynavax	SCB-2019 + AS03 or CpG 1018 adjuvant plus Alum adjuvant (Native like Trimeric subunit Spike Protein vaccine)	Native like Trimeric subunit Spike Protein vaccine	2	0, 21	IM	Ⅱ/Ⅲ
Vaxine Pty Ltd（豪）	Protein Subunit	COVAX-19® Recombinant spike protein + adjuvant	1		IM	Ⅰ
University of Queensland/CSL（豪）/Seqirus（英）	Protein Subunit	MF59 adjuvanted SARS-CoV-2 Sclamp vaccine	2	0, 28	IM	Ⅰ
Medigen Vaccine Biologics（台湾）/NIAID/Dynavax	Protein Subunit	MVC-COV1901 (S-2P protein + CpG 1018)	2	0, 28	IM	Ⅱ
Instituto Finlay de Vacunas, Cuba	Protein Subunit	FINLAY-FR anti-SARS-CoV-2 Vaccine (RBD + adjuvant)	2	0, 28	IM	Ⅱ
West China Hospital, Sichuan University	Protein Subunit	RBD (baculovirus production expressed in Sf9 cells) Recombinant SARS-CoV-2 vaccine (Sf9 Cell)	2	0, 28	IM	Ⅱ
University Hospital Tuebingen　独	Protein Subunit	IMP CoVac-1 (SARS-CoV-2 HLA-DR peptides)	1		SC	Ⅰ
COVAXX + United Biomedical Inc	Protein Subunit	UB-612 (Multitope peptide based S1-RBD-protein based vaccine)	2	0, 28	IM	Ⅱ/Ⅲ
Merck & Co. + Themis + Sharp & Dohme + Institute Pasteur + Univeristy of Pittsburgh	Replicating Viral Vector	V591-001 - Measles-vector based (TMV-o38)	1-2	0 0, 28	IM	Ⅰ/Ⅱ
Imperial College London	RNA	LNP-nCoVsaRNA	2		IM	Ⅰ
Academy of Military Science (AMS), Walvax Biotechnology （云南沃森生物）and Suzhou Abogen Biosciences	RNA	SARS-CoV-2 mRNA vaccine (ARCoV)	2	0, 14 or 0, 28	IM	Ⅰ
Medicago（カナダ　田辺三菱製薬）	VLP	Coronavirus-Like Particle COVID-19 (CoVLP)	2	0, 21	IM	Ⅱ/Ⅲ	2022/2/24　　　カナダ承認
Shenzhen Geno-Immune Medical Institute	Viral vector (Replicating) + APC	Covid-19/aAPC vaccine. The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune modulatory genes and the viral minigenes to the artificial antigen presenting cells (aAPCs).	3	0, 14, 28	SC	Ⅰ
Shenzhen Geno-Immune Medical Institute	Viral vector (Non-replicating) + APC	LV-SMENP-DC vaccine. Dendritic cells are modified with lentivirus vectors expressing Covid-19 minigene SMENP and immune modulatory genes. CTLs are activated by LV-DC presenting Covid-19 specific antigens.	１		SC & IV	Ⅰ/Ⅱ
Adimmune Corporation	Protein subunit	AdimrSC-2f (recombinant RBD +/- Aluminium)				Ⅰ
Entos Pharmaceuticals Inc.	DNA based	Covigenix VAX-001 - DNA vaccines + proteo-lipid vehicle (PLV) formulation	２	0, 14	IM	Ⅰ
Providence Health & Services	DNA based	CORVax - Spike (S) Protein Plasmid DNA Vaccine	2	0, 14	ID	Ⅰ
Chulalongkorn University	RNA based	ChulaCov19 mRNA vaccine	2	0, 21	IM	Ⅰ
City of Hope Medical Center + National Cancer Institute	Viral vector (Non-replicating)	COH04S1 (MVA-SARS-2-S) - Modified vaccinia ankara (sMVA) platform + synthetic SARS-CoV-2	1-2	0, 28	IM	Ⅰ
Aivita Biomedical, Inc. National Institute of Health Research and Development, Ministry of Health Republic of Indonesia	Viral vector (Replicating) + APC	Dendritic cell vaccine AV-COVID-19. A vaccine consisting of autologous dendritic cells loaded with antigens from SARS-CoV-2, with or without GM-CSF	1		IM	Ⅰ/Ⅱ
Codagenix/Serum Institute of India	Live attenuated virus	COVI-VAC	1 2	0,28	IN	Ⅰ
Center for Genetic Engineering and Biotechnology (CIGB)	Protein subunit	CIGB-669 (RBD+AgnHB)	3	0,14,28 or 0,28,56	IM	Ⅰ/Ⅱ
Center for Genetic Engineering and Biotechnology (CIGB)	Protein subunit	CIGB-66 (RBD+aluminium hydroxide)	3	0,14,28 or 0,28,56	IM	Ⅰ/Ⅱ
Valneva, National Institute for Health Research, United Kingdom	Inactivated Virus	VLA2001	2	0,21	IM	Ⅰ/Ⅱ
Cellid Co., Ltd.	Viral vector (Replicating)	AdCLD-CoV19 (adenovirus vector)	1		IM	Ⅰ/Ⅱ
GeneOne Life Science, Inc.	DNA based vaccine	GLS-5310	2	0,56 or 0,84	ID	Ⅰ/Ⅱ
Nanogen Pharmaceutical Biotechnology	Protein subunit	Recombinant Sars-CoV-2 Spike protein, Aluminum adjuvanted	2	0,21	IM	Ⅰ/Ⅱ
Shionogi	Protein subunit	Recombinant protein vaccine S-268019 (using Baculovirus expression vector system)	2	2,21	IM	Ⅰ/Ⅱ
Altimmune, Inc.	Viral vector (Non-replicating)	AdCOVID, Adenovirus-based platform expresses the receptor-binding domain (RBD) of the Sars-Cov-2 spike protein	1-2		IN	Ⅰ
University Medical Center Groningen + Akston Biosciences Inc.	Protein subunit	SARS-CoV-2-RBD-Fc fusion protein			SC or IM	Ⅰ/Ⅱ
Erciyes University	Inactivated Virus	ERUCOV-VAC, inactivated virus	2	0,21	IM	Ⅰ
Vaccine and Infectious Disease Organization (VIDO) +Seppic and the Vaccine Formulation Institute (VFI)	Protein subunit	COVAC-1 and COVAC-2 sub-unit vaccine (spike protein) + SWE adjuvant	2	0,28	IM	Ⅰ/Ⅱ